AFFINITY PLUS Trademark

Trademark Overview

On Wednesday, May 29, 2019, a trademark application was filed for AFFINITY PLUS with the United States Patent and Trademark Office. The USPTO has given the AFFINITY PLUS trademark a serial number of 88450949. The federal status of this trademark filing is REGISTERED as of Tuesday, April 6, 2021. This trademark is owned by Integrated DNA Technologies, Inc.. The AFFINITY PLUS trademark is filed in the Chemical Products category with the following description:

Reagents for scientific or medical research use, namely, oligonucleotides and chemicals used for their synthesis
affinity plus

General Information

Serial Number88450949
Word MarkAFFINITY PLUS
Filing DateWednesday, May 29, 2019
Status700 - REGISTERED
Status DateTuesday, April 6, 2021
Registration Number6316307
Registration DateTuesday, April 6, 2021
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 24, 2019

Trademark Statements

NOT AVAILABLE"AFFINITY"
Goods and ServicesReagents for scientific or medical research use, namely, oligonucleotides and chemicals used for their synthesis

Classification Information

International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateThursday, June 13, 2019
Primary Code001
First Use Anywhere DateWednesday, October 2, 2019
First Use In Commerce DateWednesday, October 2, 2019

Trademark Owner History

Party NameIntegrated DNA Technologies, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCoralville, IA 52241
US
Party NameIntegrated DNA Technologies, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCoralville, IA 52241
US
Party NameIntegrated DNA Technologies, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCoralville, IA 52241
US

Trademark Events

Event DateEvent Description
Saturday, June 1, 2019NEW APPLICATION ENTERED
Thursday, June 13, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, June 19, 2019ASSIGNED TO EXAMINER
Monday, June 24, 2019NON-FINAL ACTION WRITTEN
Monday, June 24, 2019NON-FINAL ACTION E-MAILED
Monday, June 24, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, October 15, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, October 21, 2019ASSIGNED TO LIE
Monday, October 21, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, October 21, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, November 15, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 4, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 24, 2019PUBLISHED FOR OPPOSITION
Tuesday, December 24, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 18, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, June 29, 2020TEAS STATEMENT OF USE RECEIVED
Monday, July 20, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, June 29, 2020USE AMENDMENT FILED
Monday, July 20, 2020STATEMENT OF USE PROCESSING COMPLETE
Monday, August 10, 2020SU - NON-FINAL ACTION - WRITTEN
Monday, August 10, 2020NON-FINAL ACTION E-MAILED
Monday, August 10, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, February 8, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 9, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 9, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 2, 2021ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, March 3, 2021NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, April 6, 2021REGISTERED-PRINCIPAL REGISTER
Monday, April 6, 2026COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED

Related Keywords

plus affinity chemicals used their synthesis oligonucleotides namely scientific medical research reagents